The following is a press release written by Sano Genetics (although I added bold text):

Sano Genetics, a healthtech start-up co-founded by three University of Cambridge genomics postgraduates, has raised USD11 million in a Series A funding round led by MMC Ventures, with further funding from Episode 1, Seedcamp and several angel investors.

These include Paul Forster, a co-founder and former CEO of Indeed, Paul Wicks, former VP of innovation at PatientsLikeMe, and Margo Georgiadis, the former CEO of Ancestry.com.

The startup has developed a software platform that connects patients living with rare and chronic conditions, such as Long Covid, multiple sclerosis, Parkinson’s and Alzheimer’s, directly with biotech and pharma companies leading personalised medicine research – a market worth USD52.4 billion in 2020 and predicted to reach USD112.8 billion by 2027.

It also offers its biotech and pharma clients the ability to power branded portals for participant recruitment and engagement, on a national or global scale.

Sano Genetics raised GBP500k in pre-seed funding in 2018, and GBP2.5 million in seed funding in 2020, which helped get the platform into the hands of more customers, including precision medicine developers BenevolentAI, ESCAPE Bio, and population-scale biobanks such as the NIHR BioResource.